Skip to Content

Tag: Dan Greenleaf


Specialty Providers

BioScrip revenues are down, but core product mix is up

August 11, 2017Theresa Flaherty, Managing Editor

DENVER - BioScrip's net revenues decreased 6.2% in the second quarter of 2017, but CEO Dan Greenleaf said in an earnings call the company was hitting targets.BioScrip reported net revenues of $218.1 million for the second quarter of 2017 compared to $232.4 million for the same period a year ago. Net loss was $29.2 million vs. $8.2 million.Still, BioScrip increased its core product mix to 73.1%, compared to 60.3% a year ago, with an ultimate goal of 85%.“Overall, our turnaround plan is on schedule,”...

BioScrip, Dan Greenleaf, Home Infusion


Read Full Articlered right arrow icon

Also Noted

BioScrip earnings 'in line' with expectations

May 5, 2017HME News Staff

DENVER - BioScrip reported net revenues of $217.8 million for the first quarter of 2017, reflecting a core revenue mix of 72% compared to 60% during the same quarter in 2016. Net loss was $19 million and adjusted EBITD was 5.2 million. For the full year 2017, BioScrip expects to achieve adjusted EBITDA in the range of $45 million to $55 million. “I am pleased with our company's first quarter performance, which was in line with our plan,” said Dan Greenleaf, president and CEO in a press...

BioScrip, Dan Greenleaf, Home Infusion Therapy


Read Full Articlered right arrow icon

Specialty Providers

'Clear mission' says Greenleaf

March 22, 2017Theresa Flaherty, Managing Editor

With one full financial quarter under his belt, BioScrip President and CEO Dan Greenleaf says the company is reinvigorated and on track to right itself.“We've got a highly engaged organization that is very clear about the mission of the organization,” said Greenleaf, who took the reins in September after several disappointing quarters for the company. “We aren't firing on all cylinders yet, but I would submit we are firing on most.”A key tenet of BioScrip's turnaround plan...

BioScrip, Dan Greenleaf, Home Infusion Therapy


Read Full Articlered right arrow icon

Specialty Providers

CORE is key to BioScrip reversal

March 10, 2017Theresa Flaherty, Managing Editor

DENVER - BioScrip has pushed closer to its goal of having its core home infusion business make up 85% of its overall revenue, said company executives on a recent earnings call.On March 3, BioScrip reported net revenues of $166.8 million for its core business for the fourth quarter, an increase of $21.9 million or 15.1% compared to the same quarter in 2015. The core business grew to represent 70% of the company's total revenues in the quarter.“We've got a great sales team in place, and some...

BioScrip, Dan Greenleaf, Home Infusion, payment gap


Read Full Articlered right arrow icon

Specialty Providers

Greenleaf: 'Home infusion is a valuable option'

June 20, 2014Theresa Flaherty, Managing Editor

In his six years in the home infusion business, Dan Greenleaf has seen his share of challenges. Still, the new CEO of Home Solutions says it's an exciting place to be. He spoke with HME News recently about home infusion's role in the “medical neighborhood.”HME News: Why is this an exciting time for home infusion?Dan Greenleaf: We have a broken healthcare system in the sense that we are treating patients extremely inefficiently. The home is the preferred choice for the patient, for the...

Dan Greenleaf, Home Infusion, Home Solutions


Read Full Articlered right arrow icon